Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

Table 2 Probability of target attainment based on Monte Carlo simulations

CrCl (mL/min)	Total daily dose (mg)	Dose (mg)	Dosing interval (h)	Perfusion duration (h)	Probability of Cmin (%)
CrCl (mL/min)	Total daily dose (mg)	Dose (mg)	Dosing interval (h)	Perfusion duration (h)	> 12 mg/L	> 46 mg/mL
160	3000	1500	12	0.5	51	0
				4	62	< 0.5
				6	70	< 0.5
		1000	8	0.5	65	0
				4	81	< 0.5
				6	88	1
		3000	24	24	98	1
	4500	1500	8	0.5	89	5
200	3000	1000	8	6	69	< 0.5
	3000	3000	24	24	89	< 0.5
	4500	1500	8	4	84	1
	4500			6	92	2
	6000	2000	8	0.5	84	5
240	3000	3000	24	24	68	< 0.5
	4500	1500	8	4	61	< 0.5
				6	74	< 0.5
		4500	24	24	96	1
	6000	2000	8	4	80	2
				6	89	3
		6000	24	24	99	7

Cmin minimum levetiracetam concentration, CrCl creatinine clearance. In bold, PTA (probability of Cmin higher than 12 mg/L) > 80%

ISSN: 2052-0492